Phase 2 N=12 Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia
Hypophosphatasia
Primary: Maximum Percent Change From Baseline in Extracellular Inorganic Pyrophosphate (PPi) — -36.46; -77.31; -56.88 percent change — p=0.0005
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=13 A Dose Escalation Study in de Novo Renal Transplantation
Kidney Transplantation
Primary: Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0. — 2; 4; 7; 0 Participants
Phase 2 N=155 A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833
Obesity
Primary: Percentage Change From Baseline in Body Weight (%) After 13 Weeks of Treatment — -0.15; -1.57; -2.94 % Change from Baseline — p=0.0756
Phase 2 N=40 A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE) — 8; 8; 11; 13 Participants
Phase 2 N=1,437 A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults
Infections, Meningococcal
Primary: Number of Participants With Solicited Administration Site Events in Study Phase I (Safety Lead-in) — 0; 0; 0; 0 Participants
Phase 2 N=138 Cardiometabolic Effects of Pecans as a Snack
Cardiovascular Diseases
Primary: Flow Mediated Dilation — 7.07; 7.25 percent point change in arterial diamete
Phase 2 N=42 Preventing Postpartum Depression With Intranasal Oxytocin
Depression, Postpartum · Anxiety
Primary: Treatment Effect on Mother-infant Bonding — 99.33; 99.35; 101.11; 97.90 score on a scale — p=0.5
Phase 2 N=37 Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
Rectal Cancer
Primary: Clinical Complete Response (cCR) — 0.24 Proportion of Participants
Phase 2 N=88 A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
Chronic Migraine · Chronic Migraine, Headache · Chronic Migraine Without Aura
Primary: Mean Change in the Number of Monthly Migraine Headache Days — -8.17; -7.78; -5.77 number of days
Phase 2 N=16 Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy
Generalized Lipodystrophy
Primary: Absolute Change From Baseline in Participants With Elevated Baseline Hemoglobin A1c (HbA1c ≥7%) at Week 8 — -0.1; 0.2 millimoles per mole (mmol/mol)
Phase 2 N=38 Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases
Rectal Cancer · Liver Metastases
Primary: Quality of Surgery for Primary Tumor — 2; 1; 15; 19 Participants — p=0.719
Phase 2 N=151 Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer
Breast Neoplasms · Breast Cancer · Estrogen-receptor Positive Breast Cancer
Primary: Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=316 A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
Advanced Solid Tumor
Primary: Broad Panel and Pediatric Cohorts: Objective Response Rate (ORR) Based on Response Assessment in Neuro-Oncology (RANO) as Assessed by Independent Review Committee (IRC)…
Phase 2 N=70 A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber
Conjunctivitis, Allergic
Primary: Subject-Reported Ocular Itching Score — 16.410; 16.964; 22.310 units on a scale
Phase 2 N=94 A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
Advanced Hepatocellular Carcinoma
Primary: Objective Response Rate (ORR) as Assessed by the Investigator — 37.1; 40.6 percentage of participants